R
3.18
-0.03 (-0.93%)
| Previous Close | 3.21 |
| Open | 3.18 |
| Volume | 1,405,144 |
| Avg. Volume (3M) | 4,154,330 |
| Market Cap | 343,134,720 |
| Price / Book | 0.980 |
| 52 Weeks Range | |
| Earnings Date | 6 Nov 2025 |
| Diluted EPS (TTM) | -2.63 |
| Total Debt/Equity (MRQ) | 6.15% |
| Current Ratio (MRQ) | 9.19 |
| Operating Cash Flow (TTM) | -208.66 M |
| Levered Free Cash Flow (TTM) | -109.28 M |
| Return on Assets (TTM) | -34.80% |
| Return on Equity (TTM) | -60.45% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Mixed |
| Biotechnology (Global) | Mixed | Mixed | |
| Stock | Rocket Pharmaceuticals, Inc. | Bearish | Bearish |
AIStockmoo Score
0.8
| Analyst Consensus | 2.0 |
| Insider Activity | NA |
| Price Volatility | 0.5 |
| Technical Moving Averages | 2.5 |
| Technical Oscillators | -2.0 |
| Average | 0.75 |
|
Rocket Pharmaceuticals Inc is a late-stage biopharmaceutical company. It is focused on the development of gene therapies for rare and devastating pediatric diseases. The pipeline products of the company include RP-A501 for Danaon Disease, RP-L102 for Fanconi Anemia, RP-L201 for Leukocyte Adhesion, RP-L301 for Pyruvate Kinase Deficiency, and RP-L401 for Infantile Malignant Osteopetrosis. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Growth |
| % Held by Insiders | 2.73% |
| % Held by Institutions | 93.45% |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 11.00 (Chardan Capital, 245.91%) | Buy |
| Median | 10.00 (214.47%) | |
| Low | 7.00 (Leerink Partners, 120.13%) | Hold |
| Average | 9.20 (189.31%) | |
| Total | 4 Buy, 1 Hold | |
| Avg. Price @ Call | 3.33 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Leerink Partners | 03 Oct 2025 | 7.00 (120.13%) | Hold | 3.15 |
| B of A Securities | 20 Aug 2025 | 10.00 (214.47%) | Buy | 3.75 |
| 25 Jul 2025 | 4.00 (25.79%) | Hold | 3.14 | |
| Chardan Capital | 20 Aug 2025 | 11.00 (245.91%) | Buy | 3.75 |
| 11 Aug 2025 | 11.00 (245.91%) | Buy | 2.92 | |
| Cantor Fitzgerald | 08 Aug 2025 | 8.00 (151.57%) | Buy | 2.86 |
| Canaccord Genuity | 25 Jul 2025 | 10.00 (214.47%) | Buy | 3.14 |
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |